Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy

Inclusion Criteria

• •1. Subjects must give appropriate written informed consent prior to participation in the study.
• •2. Subjects must be women or men age 18+.
• •3. Subjects must be receiving neoadjuvant chemotherapy for breast cancer. All chemotherapy types and regimens are acceptable (systemic therapy will determined by the overseeing medical oncologist).
• •4. Biopsy-confirmed diagnosis of invasive breast cancer (i.e. ER+/-, PR+/-, HER2+/-).
• •5. Stage I-III disease according to the AJCC v7 criteria.